To compare an investigational nasal spray to placebo nasal spray (no active ingredients). The study will determine how well the study medication works for the treatment of nocturia.
To estimate the per-patient clinical response to CAZ-AVI and BAT at TOC in the treatment of selected serious infections caused by ceftazidime-resistant Gram-negative pathogens.
To further evaluate the clinical response to CAZ-AVI and BAT at different visits and in patient subgroups (including entry diagnosis, pathogen, resistance mechanism, and previously failed treatment class)
To estimate the microbiological response to CAZ-AVI and BAT in the treatment of selected serious infections caused by ceftazidime-resistant Gram-negative pathogens
To evaluate the reasons for treatment change and/or discontinuation for CAZ-AVI and BAT
To estimate the 28-day, all-cause mortality among patients treated with CAZ-AVI and BAT
To evaluate the safety and tolerability profile of CAZ-AVI and BAT for the treatment of selected serious infections caused by ceftazidime-resistant Gram-negative pathogens